1471 related articles for article (PubMed ID: 18758474)
61. Histone acetyltransferase inhibitors and preclinical studies.
Manzo F; Tambaro FP; Mai A; Altucci L
Expert Opin Ther Pat; 2009 Jun; 19(6):761-74. PubMed ID: 19473103
[TBL] [Abstract][Full Text] [Related]
62. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium.
Mistry A; Glud SZ; Kjems J; Randel J; Howard KA; Stolnik S; Illum L
J Drug Target; 2009 Aug; 17(7):543-52. PubMed ID: 19530905
[TBL] [Abstract][Full Text] [Related]
63. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment.
Kanapathipillai M; Brock A; Ingber DE
Adv Drug Deliv Rev; 2014 Dec; 79-80():107-18. PubMed ID: 24819216
[TBL] [Abstract][Full Text] [Related]
64. Cancer, chitosan nanoparticles and catalytic nucleic acids.
Tan ML; Choong PF; Dass CR
J Pharm Pharmacol; 2009 Jan; 61(1):3-12. PubMed ID: 19126291
[TBL] [Abstract][Full Text] [Related]
65. Immunomodulation in cancer therapeutics.
Ehrke MJ
Int Immunopharmacol; 2003 Aug; 3(8):1105-19. PubMed ID: 12860167
[TBL] [Abstract][Full Text] [Related]
66. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects.
Wong J; Brugger A; Khare A; Chaubal M; Papadopoulos P; Rabinow B; Kipp J; Ning J
Adv Drug Deliv Rev; 2008 May; 60(8):939-54. PubMed ID: 18343527
[TBL] [Abstract][Full Text] [Related]
67. Update: the potential for chemosensitization of alkylating agents by nitroimidazoles.
Mulcahy RT
Oncology (Williston Park); 1988 Dec; 2(12):17-24, 27, 30-1 passim. PubMed ID: 3079289
[TBL] [Abstract][Full Text] [Related]
68. Nanoshell-enabled photothermal cancer therapy: impending clinical impact.
Lal S; Clare SE; Halas NJ
Acc Chem Res; 2008 Dec; 41(12):1842-51. PubMed ID: 19053240
[TBL] [Abstract][Full Text] [Related]
69. Targeting cancer with 'smart bombs': equipping plant virus nanoparticles for a 'seek and destroy' mission.
Franzen S; Lommel SA
Nanomedicine (Lond); 2009 Jul; 4(5):575-88. PubMed ID: 19572822
[TBL] [Abstract][Full Text] [Related]
70. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
71. Newer cytotoxic agents: attacking cancer broadly.
Teicher BA
Clin Cancer Res; 2008 Mar; 14(6):1610-7. PubMed ID: 18347161
[TBL] [Abstract][Full Text] [Related]
72. Patient adherence and persistence with oral anticancer treatment.
Ruddy K; Mayer E; Partridge A
CA Cancer J Clin; 2009; 59(1):56-66. PubMed ID: 19147869
[TBL] [Abstract][Full Text] [Related]
73. Colonic treatments and targets: issues and opportunities.
McConnell EL; Liu F; Basit AW
J Drug Target; 2009 Jun; 17(5):335-63. PubMed ID: 19555265
[TBL] [Abstract][Full Text] [Related]
74. Controlled application and scheduled removal of nanoparticle based chemotherapeutics (CARL) will reduce dose limiting adverse events in anticancer chemotherapy.
Pütz G; Schmah O; Eckes J; Hug MJ; Winkler K
Med Hypotheses; 2009 Apr; 72(4):393-7. PubMed ID: 19147297
[TBL] [Abstract][Full Text] [Related]
75. Nanoparticles in photodynamic therapy: an emerging paradigm.
Chatterjee DK; Fong LS; Zhang Y
Adv Drug Deliv Rev; 2008 Dec; 60(15):1627-37. PubMed ID: 18930086
[TBL] [Abstract][Full Text] [Related]
76. Therapeutic and diagnostic applications of dendrimers for cancer treatment.
Wolinsky JB; Grinstaff MW
Adv Drug Deliv Rev; 2008 Jun; 60(9):1037-55. PubMed ID: 18448187
[TBL] [Abstract][Full Text] [Related]
77. Lycopene in cancer prevention and treatment.
Seren S; Lieberman R; Bayraktar UD; Heath E; Sahin K; Andic F; Kucuk O
Am J Ther; 2008; 15(1):66-81. PubMed ID: 18223356
[TBL] [Abstract][Full Text] [Related]
78. Emerging use of nanoparticles for the therapeutic ablation of urologic malignancies.
Stern JM; Cadeddu JA
Urol Oncol; 2008; 26(1):93-6. PubMed ID: 18190837
[TBL] [Abstract][Full Text] [Related]
79. Novel metal-based anticancer drugs: a new challenge in drug delivery.
Lainé AL; Passirani C
Curr Opin Pharmacol; 2012 Aug; 12(4):420-6. PubMed ID: 22609113
[TBL] [Abstract][Full Text] [Related]
80. Tumor targeted nanoparticles: a modern day Trojan horse.
Gilmore D; Colson YL
Semin Thorac Cardiovasc Surg; 2011; 23(1):10-1. PubMed ID: 21807291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
